InnoCan Pharma Corporation (INNO.CN)
- CNW Group
Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has received a positive response from the U.S. Food and Drug Administration (FDA) following Innocan's successful pre-Investigational New Drug (pre-IND) Type B meeting with the FDA held in July, for its lead drug product Liposomal Technology-CBD (LPT-CBD).
- CNW Group
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the "Units") at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the "Offering").
- CNW Group
Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the registration of all its products under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
